Welsh et al. reported that ERCC1 expression in bladder cancer cell lines was higher than that in testis tumor cell lines, and it led to less sensitivity to cisplatin-based chemotherapy in bladder cancer than that in testicular cancer [30]. Here, ERCC1 is linked to urinary bladder carcinoma.